Abstract

BackgroundCost-effectiveness analysis has been recognized as an important tool to determine the efficiency of healthcare interventions and services. There is a need for evaluating the reporting of methods and results of cost-effectiveness analyses and establishing their validity. We describe and examine reporting characteristics of methods and results of cost-effectiveness analyses conducted in Spain during more than two decades.MethodsA methodological systematic review was conducted with the information obtained through an updated literature review in PubMed and complementary databases (e.g. Scopus, ISI Web of Science, National Health Service Economic Evaluation Database (NHS EED) and Health Technology Assessment (HTA) databases from Centre for Reviews and Dissemination (CRD), Índice Médico Español (IME) Índice Bibliográfico Español en Ciencias de la Salud (IBECS)). We identified cost-effectiveness analyses conducted in Spain that used quality-adjusted life years (QALYs) as outcome measures (period 1989–December 2014). Two reviewers independently extracted the data from each paper. The data were analysed descriptively.ResultsIn total, 223 studies were included. Very few studies (10; 4.5 %) reported working from a protocol. Most studies (200; 89.7 %) were simulation models and included a median of 1000 patients. Only 105 (47.1 %) studies presented an adequate description of the characteristics of the target population. Most study interventions were categorized as therapeutic (189; 84.8 %) and nearly half (111; 49.8 %) considered an active alternative as the comparator. Effectiveness of data was derived from a single study in 87 (39.0 %) reports, and only few (40; 17.9 %) used evidence synthesis-based estimates. Few studies (42; 18.8 %) reported a full description of methods for QALY calculation. The majority of the studies (147; 65.9 %) reported that the study intervention produced “more costs and more QALYs” than the comparator. Most studies (200; 89.7 %) reported favourable conclusions. Main funding source was the private for-profit sector (135; 60.5 %). Conflicts of interest were not disclosed in 88 (39.5 %) studies.ConclusionsThis methodological review reflects that reporting of several important aspects of methods and results are frequently missing in published cost-effectiveness analyses. Without full and transparent reporting of how studies were designed and conducted, it is difficult to assess the validity of study findings and conclusions.Electronic supplementary materialThe online version of this article (doi:10.1186/s13643-015-0181-5) contains supplementary material, which is available to authorized users.

Highlights

  • Cost-effectiveness analysis has been recognized as an important tool to determine the efficiency of healthcare interventions and services

  • Cost-effectiveness analysis has been recognized as an important tool to assist clinicians, scientists and policymakers in determining the efficiency of healthcare interventions, guiding societal decision-making on the financing of healthcare services and establishing research priorities

  • Given that the information provided by cost-effectiveness analysis has the potential to impact population health and health services, there is a need for evaluating the reporting of methods and results of cost-effectiveness analyses and establishing their validity to inform policymaking [1,2,3,4]

Read more

Summary

Introduction

Cost-effectiveness analysis has been recognized as an important tool to determine the efficiency of healthcare interventions and services. There is a need for evaluating the reporting of methods and results of costeffectiveness analyses and establishing their validity. Cost-effectiveness analysis has been recognized as an important tool to assist clinicians, scientists and policymakers in determining the efficiency of healthcare interventions, guiding societal decision-making on the financing of healthcare services and establishing research priorities. Given that the information provided by cost-effectiveness analysis has the potential to impact population health and health services, there is a need for evaluating the reporting of methods and results of cost-effectiveness analyses and establishing their validity to inform policymaking [1,2,3,4]. The central government of Spain is the main decision-maker in pricing and reimbursement related to new medicines and healthcare technologies, with a high decentralization of health jurisdictions in several regional health services, but traditionally, there have been no national requirements related to the costeffectiveness for making coverage decisions

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call